Background/Aims: mTOR is an important therapeutic target for human head and neck squamous cell carcinoma (HNSCC). The current study tested the anti-HNSCC cell activity by a mTOR kinase inhibitor CZ415. Methods: HNSCC cells were treated with CZ415. Cell death was tested by lactate dehydrogenase (LDH) assay and MTT assay. Cell proliferation was tested by BrdU ELISA assay and [H 3 ] thymidine incorporation assay, with apoptosis assayed by the TUNEL staining. A Western blotting assay was applied to test autophagy-associated proteins, mTOR and signalings. The nude mice xenograft model was established to study CZ415-mediated anti-tumor activity. Results: In established (SCC-9, SQ20B and A253 lines) and primary human HNSCC cells, CZ415 efficiently inhibited cell survival and proliferation. CZ415 blocked mTORC1/2 activation and inhibited ERK in HNSCC cells. CZ415 provoked feedback autophagy activation. Conversely, autophagy inhibitors (3-methyladenine and chloroquine) or Beclin-1 shRNA sensitized CZ415-induced HNSCC cell death. In vivo, CZ415 gavage inhibited SCC-9 tumor growth in nude mice, showing higher efficiency against Beclin-1-silenced tumors. Conclusion: CZ415 inhibits HNSCC cell growth in vitro and in vivo. Inhibition of autophagy can further sensitize CZ415 against HNSCC cells.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous family of carcinomas [1] [2] [3] . HNSCC is often diagnosed at late-or advanced-stage [1] [2] [3] [4] . The lack of effective treatment can cause HNSCC progression [1] [2] [3] [4] . Deregulation of mTOR (mammalian target of rapamycin) signaling plays a critical role in HNSCC progression [5] [6] [7] . mTOR activation promotes a number of key cancerous behaviors [8] [9] [10] [11] . Therefore, mTOR is an important therapeutic target for HNSCC [5] [6] [7] . Our previous study has demonstrated that GSK1059615, a novel PI3K-mTOR dual inhibitor, inhibited HNSCC cell growth in vitro and in vivo [12] .
Primary culture human cancer cells and epithelial cells
The detailed protocols of primary culture of human oral cavity carcinoma (OCC) cells and oral (cavity) epithelial cells were described in our previous study [12] . Four lines of primary OCC cells ("OCC1-4") and two lines of oral epithelial cells ("Oepi1-2") were established [12] . The protocols were approved by the Institutional Ethics Committee and Internal Review Committee of authors' institutions, and were conducted according to World Medical Association (Declaration of Helsinki). The privacy rights of human subjects must always be observed.
MTT assay
To test cell viability, the routine MTT (Sigma) assay was performed with manufactory's recommendation [12, 19] . MTT OD at 590 nm was recorded.
Clonogenicity assay SCC-9 cells (1×10 4 per 10-cm dish) were originally plated in 0.5% agarose-containing complete medium. After applied CZ415 treatment of 10 days, the survival SCC-9 colonies were manually counted.
Lactate dehydrogenase (LDH) assay
Release of LDH to the conditional medium is a characteristic marker of cell death. We utilized the twostep LDH assay kit (Takara, Tokyo, Japan) [20] to examined medium LDH content [12, 20] .
In vitro proliferation assay
Test of cell proliferation by the BrdU ELISA assay or the [H 3 ] thymidine incorporation assay was described in detail in our previous studies [12, 15] . The value of treatment groups was always normalized to that of the untreated control group.
TUNEL assay
The terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay allows quick and easy demonstration of cell apoptosis. In line with our previous study [12] , The TUNEL In Situ Cell Death Detection Kit (Roche, Shanghai, China) was utilized to stain nuclei of apoptotic cells. TUNEL ratio of 200 cells per treatment was recorded.
Western blotting assay
Following the applied treatment, cells or tumor tissues were lysed via RIPA lysis buffer (Biyuntian, Shanghai, China). For each treatment, thirty µg of lysate proteins per lane were separated by the SDS-polyacrylamide gel electrophoresis (PAGE) gel (10-12.5%), which were then transferred to the polyvinylidene fluoride (PVDF) membrane (Millipore, Shanghai, China). After blocking in 10% milk, the blot was incubated with designated primary and corresponding secondary antibodies [21] . The ECL reagents (Amersham Biosciences, Shanghai, China) were employed to detect antibody-antigen binding. The total gray of each band was quantified via Image J software (NIH).
shRNA knockdown of Beclin-1
The two verified Beclin-1-targeting lentiviral shRNAs ("a/b", with non-overlapping sequence), as well as the scramble control lentiviral shRNA were provided by Dr. Jiang [22] . The lentiviral shRNA was added to cultured SCC-9 cells (50% confluence in basic medium) for 12 hours. Cells were then subjected to puromycin (5 μg/mL, Sigma) selection for additional 6 passages. Beclin-1 expression in the stable cells was tested by Western blotting assay.
Tumor xenograft assay
Five millions of SCC-9 cells or primary human OCC cells per mouse were inoculated s.c. into the female nude mice (5-6 week age, 18.2-19.1 grams in weight). Within 2-3 weeks, xenograft tumors were established, and tumor volumes were around 0.1 cm 3 . The mice were then randomly assigned into groups as mentioned in the text (n=10 per group). Tumor volume was measured once every week as described [12] . Estimated daily tumor growth was calculated according to our previous study [12] . The animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of authors institutions and comply with the National Institutes of Health guide for the care and use of Laboratory animals.
Immunohistochemistry (IHC) staining
The detailed protocol of IHC staining was described in published studies [23] . Tumor tissues were first fixed, embedded in paraffin, and cut into the 4 μm sections. The paraffin sections were deparaffined and incubated with 3% hydrogen peroxide. Then, the sections were blocked, incubated with anti-S6K1 antibody (1 : 100) and horseradish peroxidase (HRP)-coupled secondary antibody (Santa Cruz). The peroxidase activity was visualized through the 3-amino-9-ethyl-carbazol (AEC) and MAYER'S method (Merck) [23] .
Statistical analysis
The results of one whole set of experiment were shown. Results were compared by one-way analysis of variance (ANOVA) followed by Turkey's test. Values of p < 0.05 were considered as statistically significant. Experiments in Figs 1-5 were repeated at least three times, and similar results were obtained each time.
Results

CZ415 inhibits HNSCC cell survival
First, SCC-9 human HNSCC cells [12] were treated with gradually-increased concentrations of CZ415 (from 1 to 300 nM). MTT viability assay results in Fig. 1A show that CZ415 dose-dependently inhibited SCC-9 cell survival (MTT OD). CZ415 IC-50 was close to 30-100 nM (72-96 hour treatment) (Fig. 1A) . At a low concentration (1 nM), CZ415 was however ineffective (Fig. 1A) . CZ415 displayed a time-dependent response in inhibiting SCC-9 cell viability (Fig. 1A) . It requires at least 48-72 hours to exert significant cytotoxicity (Fig. 1A) . The clonogenicity assay shows that CZ415 at 10-300 nM significantly reduced the number of viable SCC-9 colonies (Fig. 1B) . Additionally, CZ415 induced LDH release in SCC-9 cells, confirming cell death (Fig. 1C) .
SQ20B and A253 HNSCC cells were treated with CZ415 as well. A MTT assay shows that CZ415 (100 nM, 72 hours) was cytotoxic to these cells (Fig. 1D) . Conversely, the same CZ415 treatment (100 nM, 72 hours) was non-cytotoxic to the oral epithelial cell ("Oepi1/2" [12] ). CZ415's potential effect in the primary human oral cavity carcinoma (OCC) cells was tested. As described previously [12] , four lines of primary OCC cells (namely "OCC1/2/3/4") were established. Following treatment of CZ415 (100 nM, 72 hours), a MTT assay shows that CZ415 decreased viability of the primary OCC cells (Fig. 1E) . The MTT assay results in Fig. 1F show that CZ415 was significantly more potent in inhibiting SCC-9 cell viability than the same concentration of rapamycin and RAD001, two mTORC1 inhibitors [24] . CZ415 was even more efficient than the mTOR kinase inhibitor OSI-027 [25] (Fig. 1F) . Collectively, these results suggest that CZ415 inhibits HNSCC cell survival.
CZ415 inhibits HNSCC cell proliferation
As described [12] , the BrdU ELISA assay and [H 3 ] thymidine incorporation assay were performed to test cell proliferation. Results show that CZ415 dose-dependently inhibited were treated with designated concentration of CZ415 ("CZ"), rapamycin ("Rap"), RAD001 ("RAD") or OSI-027 ("OSI"), cells were further cultured for indicated time, and cell proliferation and expression of proliferation-associated proteins were tested by assays mentioned in the text. Cyclin D1 and Cyclin B1 expression were quantified and normalized to Tubulin (C). For each assay, n=5. * p<0.05 vs. group "C". 2B) were significantly decreased after CZ415 (30-300 nM) treatment. Additionally, cyclin D1 and cyclin B1 were downregulated in CZ415-treated cells (Fig. 2C) .
In SQ20B and A253 cells, BrdU incorporation was inhibited after CZ415 treatment as well (Fig.  2D ). CZ415 was ineffective on BrdU incorporation in the oral epithelial cell ("Oepi1/2") ( Fig. 2D) . Significantly, BrdU ELISA OD was decreased by CZ415 in the primary HNSCC cells (Fig. 2E) . Again, CZ415 was more efficient in suppressing SCC-9 cell proliferation than rapamycin, RAD001 and OSI-027 (Fig. 2F) . Collectively, these results show that CZ415 inhibits HNSCC cell proliferation.
CZ415 blocks mTORC1/2 activation and inhibits ERK activation in HNSCC cells
CZ415 is a mTOR kinase inhibitor [16, 17, 26] . mTOR signaling in CZ415-treated cells was tested. As shown, in SCC-9 cells, phosphorylation ("p-") of the mTORC1 substrate S6K1 (Ser-389) and the mTORC2 substrate AKT (Ser-473) were inhibited by CZ415 (Fig. 3A) . p-AKT at Thr-308 was not significantly affected (Fig. 3A) . Importantly, CZ415 inhibited ERK activation, and p-ERK1/2 (T202/ Y204) level decreased in SCC-9 cells (Fig. 3A) . The basal activation of mTORC1 (p-S6K1) and mTORC2 (p-AKT Ser-473) were high in the primary human OCC cells ("OCC-1/4"), but low in the oral epithelial cells ("Oepi1/2") (Fig. 3B) . In the primary human OCC cells ("OCC1"), CZ415 blocked mTORC1 (p-S6K1) and mTORC2 (p-AKT Ser-473) activation, whiling inhibiting ERK activation (Fig. 3C) . p-AKT at Thr-308 was again not affected by CZ415 (Fig. 3C) . Conversely, C CZ415 (100 nM), 6h . SCC-9 cells were pretreated with 3-methyladenine (3-MA, 10 mM) or chloroquine (Cq, 100 μM) for 1 hour, followed by CZ415 (100 nM) treatment for applied time; Cell viability (MTT assay, C), cell death (LDH release assay, D) and apoptosis (TUNEL assay, E) were tested. Blot data were quantified (A and B). For each assay, n=5. * p<0.05 vs. group "C" (C-E). # p<0.05 vs. "DMSO" (0.1%) (C-E). Experiments in this Fig. were 3D ). These might explain the in-effectiveness of the mTOR kinase inhibitor in epithelial cells ( Fig. 1 and 2 ).
Autophagy inhibition sensitizes CZ415-induced SCC-9 cell death
AKT-mTOR in-activation can induce feedback autophagy activation, which serves as a chemo-resistance factor. Autophagy-associated proteins in CZ415-treated HNSCC cells were then tested. CZ415-induced mTORC1/2 inactivation in SCC-9 cells lasted for 12-24 hours (Fig. 4A) . Significantly, CZ415 induced Beclin-1, ATG-5, and ATG-7 upregulation, light chain 3B (LC3B)-I to LC3B-II conversion and p62 degradation (Fig. 4B) , indicating autophagy activation [22, 27, 28] . Two well-known autophagy inhibitors, 3-methyladenine (3-MA) [29] , chloroquine (Cq) [30] , were applied next. CZ415-induced SCC-9 cell viability reduction (Fig. 4C ) and cell death (Fig. 4D) were significantly potentiated by 3-MA or Cq. Therefore, autophagy inhibition can sensitize CZ415-induced SCC-9 cell death. Intriguingly, SCC-9 cell apoptosis was only induced by CZ415 when combined with the autophagy inhibitors (Fig.  4E) . Feedback autophagy activation could be the reason of non-apoptosis in CZ415-treated cells. Inhibition of autophagy can re-provoke SCC-9 cell. The autophagy inhibitors alone failed to affect cell survival and apoptosis ( Fig. 4C-E) .
Beclin-1 knockdown sensitizes CZ415
A shRNA method was utilized to knockdown Beclin-1, which is a key autophagy protein [31, 32] . Two different Beclin-1-targeting shRNAs ("a/b"), with non-overlapping sequences, were from Dr. Jiang' [22] . A Western blotting assay confirm that both shRNAs induced significant Beclin-1 downregulation in SCC-9 cells (Fig. 5A) . Consequently, CZ415-induced SCC-9 cell viability reduction (Fig. 5B ) and cell death (Fig. 5C) were significantly potentiated. CZ415 induced apoptosis activation in Beclin-1-silenced SCC-9 cells (Fig. 5D ). Beclin-1 shRNA alone had no significant effect on SCC-9 cell survival, death and apoptosis (Fig. 5B-D) . Therefore, Beclin-1 shRNA results confirm that autophagy activation is a key resistance factor of CZ415. In A253 cells (Fig. 5E ) and the primary human OCC cells ("OCC1 line", Fig. 5F ), the autophagy inhibitor 3-MA significantly potentiated CZ415-induced viability reduction. In contrast, CZ415 and 3-MA combination was non-cytotoxic to the epithelial cells ("Oepi1", Fig. 5G ). 
Beclin-1 shRNA sensitizes CZ415-induced anti-tumor activity in vivo
At last, the CZ415's anti-tumor activity in vivo was tested. The SCC-9 tumor xenograft nude mice model was applied [12] . The tumor growth curve results, Fig. 6A , demonstrate that daily oral administration of CZ415 (20 mg/kg [16] ) significantly inhibited growth of SCC-9 tumors with control scramble shRNA ("sh-C"). The estimated daily SCC-9 tumor growth (in mm 3 per day, Fig. 6B ) and tumor weights (at week-6, Fig. 6C ) were both decreased after CZ415 treatment. The CZ415's activity in vivo was largely sensitized against tumors expressing Beclin-1 shRNA (Fig. 6A-C) . Beclin-1 shRNA alone didn't affect SCC-9 tumor growth (Fig. 6A-C) . The Mice body weight was not significantly different between the groups (Fig. 6D) . When analyzing tumor tissue samples by a Western blotting assay, we show that activation of mTORC1 (p-S6K1), mTORC2 (p-AKT Ser-473) and ERK were inhibited by CZ415 (Fig. 6E) . Beclin-1 expression was increased in CZ415-treated tumor tissues, blocked by Beclin-1 shRNA (Fig. 6E ). An immunohistochemistry (IHC) staining assay demonstrates inhibition of p-S6K1 in CZ415-treated SCC-9 tumors (Fig. 6F) .
Next, the primary human OCC cells (OCC-1 line) were inoculated via s.c. injection to the nude mice. Within 2-3 weeks, the xenograft tumors were established. Results in Fig. 6G demonstrate that the growth of the primary human OCC cells was significantly inhibited by CZ415 (20 mg/kg, daily) as well. CZ415 didn't affect the mice body weight (Fig. 6H) . mTORC1 (p-S6K1), mTORC2 (p-AKT Ser-473) and ERK activation in tumor tissues were inhibited by CZ415 as well (Fig. 6I) . Beclin-1 expression was increased, suggesting autophagy induction (Fig. 6I) . These results together suggest that autophagy inhibition by Beclin-1 shRNA sensitizes CZ415-induced anti-tumor activity in vivo. Beclin-1 shRNA ("a") or scramble control shRNA ("sh-C") were administrated daily with CZ415 (20 mg/kg body weight, gavage); Tumor volumes (A) and mice body weights (D) were recorded every week for a total of 5 weeks; Estimated daily tumor growth was also calculated (B); At the end of experiment (Week-6), SCC-9 tumors were isolated and weighted (C). At day-21, one tumor per group was isolated, tumor tissue lysates were subjected to Western blotting assay of listed proteins (E) and IHC staining assay of p-S6K1 (F, bar= 100 μm). The nude mice bearing the primary human OCC cells (OCC-1 line) were administrated daily with CZ415 (20 mg/kg body weight, gavage) or vehicle control ("Saline"), tumor volumes (G) and mice body weights (H) were recorded; At day-21, one tumor of each group was isolated, signalings were tested (I). Blot data were quantified (E). For each group, n=10 (mice). * p<0.05 vs. group of "sh-C" only (A-C).
# p<0.05 vs. "sh-C+CZ415" group (A-C). * p<0.05 vs. group of "Vehicle" (G).
A.
B. [33] . mTORC1 inhibition can also lead to feedback activation of several key oncogenic signalings, including AKT and ERK [13, [34] [35] [36] . The in vivo and clinical use of mTORC1 inhibitors is limited due to the poor solubility [37, 38] . The most important of all is that mTORC1 inhibitors have no direct inhibition on mTORC2 activity [7] .
Due to these drawbacks of mTORC1 inhibitors, recent research effects have developed "the second-generation of mTOR inhibitors" [37, 38] . These compounds, including OSI-027 [25, 39] , AZD-8055 [40] , AZD-2014 [18, 28] and XL388 [41] , directly inhibit mTOR kinase to block activity of both mTORC1 and mTORC2 [37, 38] . Here, we show that CZ415 blocked mTORC1 and mTORC2 activation, but failed to induce feedback AKT and ERK activation. CZ415 was more efficiently in killing HNSCC cells than the knonw mTORC1 inhibitors (rapamycin and RAD001).
The anti-HNSCC cell activity by CZ415 is even more potent than the mTOR kinase inhibitor OSI-027. It is possible that CZ415may have better efficiency in blocking mTOR [16] than OSI-027. It is possibly due to the co-current inhibition of ERK signaling by CZ415 as well. Another key advantage of CZ415 is its orally bioactivity. CZ415 oral administration inhibited growth of SCC-9 cells and primary human OCC cells in the nude mice. These results, together with the fact that CZ415 is non-cytotoxic to oral epithelial cells, suggest that this novel mTOR kinase could be a novel and promising anti-HNSCC agent.
When autophagy is activated, cells actively degradate its own components (i.e. organelles and cell proteins), which provides nutrition and energy for survive [42] [43] [44] . In cancer cells, many anti-cancer agents could induce feedback autophagy activation [42] [43] [44] [45] . Conversely, autophagy inhibition can sensitize the anti-cancer activity [42] [43] [44] [45] . Activated mTOR shuts down autophagy. mTOR phosphorylates unc-51-like kinase 1 (ULK1) [46] and autophagyrelated protein 13 (ATG-13) [47] to inhibit autophagy initiation. mTOR inhibition, on the other hand, shall lead to autophagy induction [48] [49] [50] . Here, we show that CZ415 induced autophagy activation in HNSCC cells. Autophagy was evidenced by Beclin-1/ATG-5/ ATG-7 upregulation, LC3B-I to LC3B-II conversion and p62 degradation. Conversely, autophagy inhibitors sensitized CZ415-induced anti-HNSCC cell activity, causing profound cell death and apoptosis.
Beclin-1 is a Bcl-2-interacting protein, it is the mammalian orthologue of the yeast protein Apg6/Vps30 [32, 51, 52] . Beclin-1 is required for autophagosome formation, also indispensable for autophagy initiation and progression [32] . Here, we show that shRNAmediated knockdown of Beclin-1 sensitized CZ415-induced anti-HNSCC cell activity. In vivo, CZ415-induced anti-tumor activity was further potentiated against Beclin-1-silenced SCC-9 tumors. These evidence suggests that Beclin-1-driven autophagy is the primary resistance factor of CZ415 in HNSCC cells.
Conclusion
Together, targeting mTOR by CZ415 inhibits HNSCC cell growth in vitro and in vivo. Inhibition of feedback autophagy can further sensitize CZ415 against HNSCC cells.
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